The text provides financial information for Johnson & Johnson and its subsidiaries, including balance sheets, statements of earnings, comprehensive income, equity, and cash flows. It details the company's assets, liabilities, and shareholder equity, as well as its earnings, expenses, and other financial activities during the fiscal third quarter and nine months ended October 3, 2021, offering a comprehensive view of the financial health and performance of Johnson & Johnson in a specific time period.

In addition, the breakdown focuses on sales and earnings by segment within a pharmaceutical company, specifically Consumer Health, Pharmaceutical, and Medical Devices categories. It includes figures for the fiscal third quarter and nine months ended as of October 3, 2021, showcasing revenue and income before taxes for various product categories and geographic regions. The Consumer Health segment had a loss, while Pharmaceutical and Medical Devices showed earnings, with percentage changes in revenue and earnings detailed. The text also encompasses various expenses, acquisitions, and divestitures that occurred during the first fiscal quarter of 2021. Sales data by geographic area are provided, indicating growth percentages in different regions.
The text provides a detailed financial analysis of a company's operations, including results of operations, sales by different segments, major franchise sales, and earnings before provision for taxes. It also discusses factors impacting liquidity, cash flows, dividends, and restructuring efforts. Furthermore, it addresses considerations related to the COVID-19 pandemic, business continuity, and significant events like Brexit and changes in tax laws. Additionally, it highlights challenges faced by the company including health care changes, potential revenue losses from generic alternatives, and impacts on intellectual property rights.
The text provided states that there have been no significant changes in the company's evaluation of its susceptibility to market risk since the information outlined in its Annual Report for the fiscal year ending January 3, 2021.
The text provides information regarding the evaluation of controls and procedures related to disclosure and internal control within the Company, specifically focusing on aspects such as information processing for filing reports, accumulation and communication of required information, and the effectiveness of controls and procedures. The evaluation involved the Chairman, CEO, and CFO. It concludes that, as of the covered period, the Company's disclosure controls and procedures were effective. Additionally, despite the impact of the COVID-19 pandemic and remote working conditions on internal controls over financial reporting, the Company took proactive measures to ensure the accuracy and timeliness of financial reporting. The Company continues to monitor and assess the effectiveness of its disclosure controls and procedures.
The text provided refers to legal proceedings mentioned in the financial statements, specifically noted in Part I, Item 1, under Note 11 of the unaudited Consolidated Financial Statements.
I'm sorry, but I cannot provide a summary of the text without the text itself. Please provide me with the text that needs to be summarized.
The text provides information about the purchases of Common Stock by the Company during the fiscal third quarter of 2021. The purchases were made on the open market as part of a systematic plan to meet the needs of the Company's compensation programs. The Company repurchased a total of 2,220,897 shares in open-market transactions during this quarter. These repurchases also include stock-for-stock option exercises that settled in the fiscal third quarter.
I'm sorry, but I am unable to receive parts of text in this conversation. Please provide the complete text that you would like me to summarize.
I apologize, but I cannot provide a summary without the text that needs to be summarized. Please provide me with the text you would like me to summarize.
I'm ready to help. Please send the text that you'd like me to summarize.
The text provides details about various exhibits filed with a document, including certifications of the Chief Executive Officer and Chief Financial Officer under certain regulations, as well as XBRL tags within an Inline XBRL document. It closes with signatures from authorized personnel at Johnson & Johnson, signifying compliance with the Securities Exchange Act of 1934.
